By allowing lower doses, the new approach could also make the treatment safer by reducing the risk of complications associated with immune system recognition that can sometimes occur with frequent injections, according to scientists at the Scripps Research Institute in La Jolla, Calif. Smaller, more potent doses may even lead to lower prices for the popular wrinkle-remover, the researchers say. Their study is published in the March 29 issue of the weekly Journal of the American Chemical Society.
Although popular for removing wrinkles, Botox is also used to treat a growing number of other conditions, including migraine headaches, lazy eyes and excessive sweating. It is developed from the botulinum neurotoxin, the most lethal poison known and a potential bioterrorist weapon. In a medical setting, small doses of a purified version of the toxin block the release of a chemical (acetylcholine) that signals muscle contraction, resulting in a localized, temporary paralysis that erases wrinkles and unwanted muscle spasms.
Kim Janda, Ph.D., a chemistry professor at Scripps and head of the research study, and his associates developed a synthetic molecule that can ‘superactivate’ the neurotoxin used in Botox by binding to specific sites on the neurotoxin protein. The synthetic molecule works by increasing the activity of an enzyme that cleaves proteins that are critical for neurotransmitter release, thereby increasing the blockage of acetylcholine and enhancing the toxin’s paralyzing effect. In laboratory studies, the researchers found that this ‘superactivator’ could boost the activity of the toxin by as much as 14 times that of the untreated toxin.
The new treatment has not yet been tested in humans or animals, the researchers say. If further studies prove successful, the technique could be available to consumers in four to six years, the researchers estimate.
"We have developed a synthetic molecule that binds to the toxin and increases its normal function," Janda says. "The discovery of small molecule activators may ultimately provide a valuable method for minimizing dosage, reducing resistance, and increasing its clinical efficacy."
One possible complication of Botox injections is that their repeated use can lead to recognition by the immune system, especially when patients are given frequent, high doses of the toxin. Higher doses can also increase the risk of adverse complications, which can include pain in the face, redness at the injection site and muscle weakness. The new ‘superactivator’ formula could allow lower doses to be administered — roughly one-tenth the normal dose — while reducing the possibility of unwanted immune complications, Janda and his associates say. Botox injections should always be performed by a qualified doctor, according to the U.S. Food and Drug Administration.
Michael Bernstein | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences